ClinicalTrials.gg
RecruitingNCT06802081TIRO-AFUpdated Jan 13, 2026

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

A Phase 2 interventional study of Tirzepatide and Placebo in Atrial Fibrillation and Obesity, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by The Cleveland Clinic · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Atrial Fibrillation by The Cleveland Clinic — 10 open to participants now, 11 under way, 1 of them phase 3. Atrial Fibrillation · The Cleveland Clinic.

Planned enrollment
4th of 13
100 · median 90
Started
2025
with 3 others
Phase 2
Only one
of the 26
Primary completion
2026-12
later than 0 of 10 live
Registered
20th of 26
by date

Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 20th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

10 of the 26 studies in Atrial Fibrillation by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Atrial Fibrillation by The Cleveland Clinic, or all of them as a file.
02

Study summary

This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.

Read the detailed description

It is estimated that 12 million people in the United States will have AFIB by 2030. The obesity epidemic and all its comorbidities such as hypertension, diabetes and sleep apnea are potent risk factors for AFIB. Weight loss has emerged as a potent treatment for AFIB. This will be a randomized double blind controlled study of patients (BMI≥ 27 kg/m2) with obesity and AFIB randomized to Tirzepatide vs. placebo in the Cleveland Clinic Health System. It is expected that the weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.

Patients who met the initial screening criteria (including presence of at least 1% AF burden during a 2 week monitoring period with an ambulatory cardiac monitor) will be invited for possible enrolment. 100 Patients will then be randomized 1:1 to Tirzepatide group versus placebo and will be followed for 12 months. AFIB burden will be assessed through FDA approved event monitor. All patients will receive standard care for management of risk factors as well as nutrition and life style modification counseling.

Management of AFIB including pharmacotherapy, ablation, and direct current cardioversion (DCC) will be at the discretion of Cleveland Clinic's cardiologists.

Patients and investigators will be blinded to treatment assignment. Assessment of the primary endpoint will be based on the blinded downloads and interpretation of event monitors.

The primary objective of the study is to examine Tirzepetide 10mg once a week vs. placebo on severity and symptom burden of AFIB at 12 months.

03

Conditions studied

  • Atrial Fibrillation
  • Obesity

Keywords

  • Atrial Fibrillation
  • Obesity
  • tirzepatide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for inclusion in this study must meet all of the following criteria:

  1. Sinus rhythm at randomization

    1. Sustained normal sinus rhythm (or)
    2. Normal sinus rhythm at office visit
  2. Age ≥18 to ≤80 years old
  3. ≥ 27 and ≤60 kg/m2
  4. AFIB criteria:

    1. Must be documented by or monitor.
    2. Must have symptomatic AFIB (Atrial Fibrillation).
    3. In terms of types of AFIB, either paroxysmal AFIB or persistent AFIB.
  5. All anti-diabetic medication (including insulin) must be stable for at least 3 months prior to enrollment,
  6. ≤10% for patients diagnosed with Type 2 Diabetes Mellitus (T2DM).
  7. Ability and willingness to give themselves the medication, comply with study requirements and provide written .

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for inclusion in this study.

  1. AFIB ablation within the last 6 months
  2. Planned ablation prior to 3 months post randomization
  3. Significant cardiac valvular disease with planned cardiac valve intervention/surgery in the next 12 months
  4. Severe uncompensated cardiopulmonary disease
  5. Class III or IV
  6. \<35% at the time of screening
  7. Hospitalization in the past 6 months for myocardial infarction, unstable angina, stroke, , or heart surgery
  8. History of solid organ transplant
  9. Type 1 diabetes mellitus or auto-immune diabetes
  10. Estimated (eGFR) \< 30 mL/min/1.73 m2 at screening or on dialysis
  11. Advanced and decompensated cirrhosis characterized by: presence of fibrosis stage 4 (cirrhosis) in liver , ascites, hepatic encephalopathy, portal hypertension, or esophageal varices.
  12. less than 9 g/dL
  13. Current participation or use of therapy or less than 3 months since participation in any drug or device trial.
  14. Liver transaminase level >300 U/L
  15. Subject reports alcohol use of on average >2 drinks/day
  16. Presence of active (except non-melanoma skin cancer)
  17. less than 3 years due to concomitant diseases
  18. Major mental health, psychological disorders, or substance abuse disorders that could disqualify the patient from metabolic surgery
  19. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study
  20. Plans to move outside the primary location of study (Northeast Ohio) within the next 12 months
  21. Any personal or family history of pancreatitis or medullary thyroid cancer or MEN2 (Multiple Endocrine Neoplasia Type 2)
  22. Current use or any use within the last 6 months of GLP-1/DPP4i (Glucagon-Like Peptide-1/Dipeptidyl Peptidase-4 inhibitor) or GIP (Gastric Inhibitory Polypeptide)/GLP-1
  23. Known to investigational product due to prior use of GLP-1/DPP4i or GIP/GLP-1
  24. Allergy to medical grade tape or adhesive
  25. Pregnant, breast-feeding or plans to become pregnant
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Tirzepatide

    Participants to inject weekly subcutaneous injections of Tirzepatide starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg) as tolerated.

    Drug: Tirzepatide

  • Placebo comparator
    Control

    Participants to inject weekly subcutaneous injections of normal saline starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).

    Drug: Placebo

Interventions

  • Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.

    Also known as: Zepbound

  • DrugPlacebo

    Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. AFib burden

    Percentage total duration of being in AFIB

    Time frame: Up to 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Jeannine Ramsey, RN, BSN · ContactRAMSEYJ8@ccf.org
    • Yuki Kuramochi, RN, BSN · Contactkuramoy@ccf.org · 216-445-4063
    • Leslie Cho, MD · Principal investigator
    • Arwa Younis, MD · Sub investigator
    • Oussama Wazni, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Jan 30, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 1, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06802081
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Apr 8, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Jeannine M Ramsey, RN, BSN
Contact
ramseyj8@ccf.org
216-559-7942
Yuki Kuramochi, RN, BSN
Contact
kuramoy@ccf.org
216-445-4063
Leslie Cho, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion